|Bid||17.31 x 3000|
|Ask||17.32 x 1400|
|Day's Range||17.26 - 17.72|
|52 Week Range||13.40 - 25.73|
|Beta (5Y Monthly)||0.20|
|PE Ratio (TTM)||28.91|
|Forward Dividend & Yield||0.44 (2.48%)|
|Ex-Dividend Date||Dec 02, 2019|
|1y Target Est||25.00|
GRFS vs. ZTS: Which Stock Is the Better Value Option?
* Companies will jointly assess and validate next-generation open and interoperable technologies * Aramco to enhance local capacity and readiness to execute pilot of advanced capabilities * Intrinsically cybersecure, interoperable automation technologies expected to bring step change improvements in operational flexibility, sustainability and efficiency MISSISSAUGA, ON, Oct. 28, 2020 /CNW/ - Schneider Electric, the leader in digital transformation of energy management and automation, and Aramco, the world's pre-eminent integrated energy and chemicals company that drives global commerce and enhances the daily lives of people around the globe, today announced they have signed a memorandum of understanding to collaborate on assessing emerging technologies based on the Open-Process Automation Standard (O-PAS).
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced that its anti-SARS-CoV-2 hyperimmune globulin, a potential treatment for COVID-19, has started a randomized controlled clinical trial to test its safety, efficacy and tolerability. This medicine provides a high and consistent concentration of purified neutralizing antibodies and could be used for both prevention and treatment of the disease. The study is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).